Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 1/2 1Phase 1 1

Status

Completed 5Terminated 1

Sponsor Class

NIH 3OTHER 2INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 17Other hematologic neoplasm 12Plasma cell 10Thoracic 7Genitourinary 6Gastrointestinal 5Tumor-Agnostic 4Myeloid 4Gynecologic 4Breast 4Head & Neck 3Other 2Sarcoma 1Other solid neoplasm 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 3Neoplasm Metastasis 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Pathologic Complete Response 1Neoplasms 1Carcinoma in Situ 1

Interventions

Docetaxel 390pembrolizumab 325Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Diphenhydramine × Genitourinary × Clear all
NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 21 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT03493945 2025-09-30

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
59 enrolled 20 charts
Genitourinary

Prostatic Neoplasms

NCT01392183 2021-09-20

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

M.D. Anderson Cancer Center

Phase 2 Completed
69 enrolled 15 charts
Genitourinary

Pathologic Complete Response, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT02441894 2017-01-24

PEGAZUS

Sanofi

Phase 4 Completed
21 enrolled
Genitourinary

Prostatic Neoplasms

NCT00887640 2014-02-26

Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer

Duke University

Phase 2 Terminated
11 enrolled 9 charts
Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00030992 2012-08-20

BMS 247550 to Treat Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
102 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡